Hearn Jay Cho

22PUBLICATIONS
124CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Apr 27, 2026
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study.

|Mar 30, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.

Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng

|Dec 09, 2025
Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Denis J Ohlstrom, William C Pilcher, Marina E Michaud

|Nov 05, 2025
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman

|Aug 13, 2025
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar

|May 03, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.

Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng

Pageof 4

Frequent Collaborators

12 joint publications

Joshua Richter

10 joint publications

Sundar Jagannath

9 joint publications

Santiago Thibaud

7 joint publications

Tarek H Mouhieddine